According to a prominent Israeli study, the natural immune protection that develops after a SARS-CoV-2 infection provides significantly more security against the Delta variant of the pandemic coronavirus than two doses of the Pfizer-BioNTech vaccine, which some scientists wish came with a “Don’t try this at home” label. Moreover, according to newly revealed data, persons who had a previous SARS-CoV-2 infection were substantially less likely than vaccinated people to obtain Delta, develop symptoms from it, or be hospitalized with severe COVID-19.
Although the study highlights the human immune system’s strength, infectious disease experts cautioned that this vaccination and others for COVID-19 remain highly protective against severe sickness and mortality. They also warn that intentionally infecting unvaccinated persons would be exceedingly dangerous. People who had previously had SARS-CoV-2 and subsequently got one dose of the Pfizer-BioNTech messenger RNA (mRNA) vaccine were found to be more resistant against reinfection than those who had the virus but had not been immunized.The study, which took place in one of the world’s most COVID-19-vaccinated countries, looked at the medical records of tens of thousands of Israelis, tracking their illnesses, symptoms, and hospitalizations between June 1 and August 14, when the Delta variation was most prevalent in Israel.
COVID-19 has already claimed the lives of almost 4 million people worldwide, and there are fears that Delta and other SARS-CoV-2 variations will be much more lethal than the original virus. The new study is based on the Maccabi Healthcare Services database, which was around 2.5 million Israelis enrolled. The probability of acquiring symptomatic COVID-19 was 27 times greater among the vaccinated, and the risk of hospitalization was eight times higher, according to one study of over 32,000 patients in the health system.